Modality
Nanobody
MOA
Anti-Aβ
Target
C5
Pathway
Fibrosis
OCD
Development Pipeline
Preclinical
~Jul 2012
→ ~Oct 2013
Phase 1
~Jan 2014
→ ~Apr 2015
Phase 2
~Jul 2015
→ ~Oct 2016
Phase 3
Jan 2017
→ May 2031
Phase 3Current
NCT03278491
385 pts·OCD
2017-01→2031-05·Recruiting
NCT04890468
371 pts·OCD
2017-08→2026-11·Not yet recruiting
NCT05001128
1,373 pts·OCD
2023-07→2025-12·Active
+1 more trial
2,771 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-12-153mo agoPh3 Readout· OCD
2026-11-288mo awayPh3 Readout· OCD
2030-03-093.9y awayPh3 Readout· OCD
2031-05-035.1y awayPh3 Readout· OCD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Recruit…
P3
Not yet…
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2025-12-15 · 3mo ago
OCD
Ph3 Readout
2026-11-28 · 8mo away
OCD
Ph3 Readout
2030-03-09 · 3.9y away
OCD
Ph3 Readout
2031-05-03 · 5.1y away
OCD
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03278491 | Phase 3 | OCD | Recruiting | 385 | PFS |
| NCT04890468 | Phase 3 | OCD | Not yet recr... | 371 | PANSS |
| NCT05001128 | Phase 3 | OCD | Active | 1373 | Mayo |
| NCT06196349 | Phase 3 | OCD | Not yet recr... | 642 | SRI-4 |
Competitors (10)